{
    "id": 4620,
    "fullName": "AURKB over exp",
    "impact": "none",
    "proteinEffect": "no effect",
    "geneVariantDescriptions": [
        {
            "description": "AURKB over exp indicates an over expression of the Aurkb protein. However, the mechanism causing the over expression is unspecified.",
            "references": [
                {
                    "id": 275,
                    "pubMedId": null,
                    "title": "External Reference Not Available (N/A)",
                    "url": "https://ckb.jax.org/about/glossaryOfTerms"
                }
            ]
        }
    ],
    "type": "non-specific",
    "gene": {
        "id": 9212,
        "geneSymbol": "AURKB",
        "terms": [
            "AURKB",
            "AIK2",
            "AIM-1",
            "AIM1",
            "ARK-2",
            "ARK2",
            "AurB",
            "aurkb-sv1",
            "aurkb-sv2",
            "IPL1",
            "PPP1R48",
            "STK-1",
            "STK12",
            "STK5"
        ]
    },
    "variant": "over exp",
    "createDate": "04/09/2015",
    "updateDate": "05/25/2018",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 15926,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, paclitaxel treatment of non-small cell lung carcinoma cells lines overexpressing Aurkb were sensitive to treatment, as demonstrated by a decrease in cell survival (PMID: 28095398).",
            "molecularProfile": {
                "id": 4417,
                "profileName": "AURKB over exp"
            },
            "therapy": {
                "id": 1103,
                "therapyName": "Paclitaxel",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 14011,
                    "pubMedId": 28095398,
                    "title": "Aurora B expression modulates paclitaxel response in non-small cell lung cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28095398"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15925,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, docetaxel treatment of non-small cell lung carcinoma cells lines overexpressing Aurkb were sensitive to treatment, as demonstrated by a decrease in cell survival (PMID: 28095398).",
            "molecularProfile": {
                "id": 4417,
                "profileName": "AURKB over exp"
            },
            "therapy": {
                "id": 720,
                "therapyName": "Docetaxel",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 14011,
                    "pubMedId": 28095398,
                    "title": "Aurora B expression modulates paclitaxel response in non-small cell lung cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28095398"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10406,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, AZD1152 (Barasertib) induced apoptosis of multiple myeloma cells overexpressing Aurkb and inhibited tumor growth in xenograft models (PMID: 18076711).",
            "molecularProfile": {
                "id": 4417,
                "profileName": "AURKB over exp"
            },
            "therapy": {
                "id": 662,
                "therapyName": "Barasertib",
                "synonyms": null
            },
            "indication": {
                "id": 9538,
                "name": "multiple myeloma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 2427,
                    "pubMedId": 18076711,
                    "title": "The selective Aurora B kinase inhibitor AZD1152 is a potential new treatment for multiple myeloma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/18076711"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 4417,
            "profileName": "AURKB over exp",
            "profileTreatmentApproaches": [
                {
                    "id": 3326,
                    "name": "AURK Inhibitor (Pan)",
                    "profileName": "AURKB over exp"
                },
                {
                    "id": 3327,
                    "name": "Aurkb Inhibitors",
                    "profileName": "AURKB over exp"
                }
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}